Wild, Damian
Grønbæk, Henning
Navalkissoor, Shaunak
Haug, Alexander
Nicolas, Guillaume P.
Pais, Ben
Ansquer, Catherine
Beauregard, Jean-Mathieu
McEwan, Alexander
Lassmann, Michael
Pennestri, Daniele
Volteau, Magali
Lenzo, Nat P.
Hicks, Rodney J.
Funding for this research was provided by:
Ipsen
University of Basel
Article History
Received: 12 June 2023
Accepted: 2 August 2023
First Online: 18 September 2023
Declarations
:
: This study was funded by Ipsen (Boulogne, France). DW: received personal fees from Ipsen and grants from Siemens Healthineers. HG: received research grants from Abbvie, Intercept, ARLA Food for Health, and ADS AIPHIA Development Services AG; received consulting fees from Ipsen, NOVO, and Pfizer; lectures for AstraZeneca and EISAI; and serves on the Data Monitoring Committee at IQVIA. CA: received personal and consulting fees from Novartis/AAA. SN and JMB: received honoraria and/or consulting fees from Ipsen and Novartis/AAA. BP and AM: received consulting fees from Ariceum and were employed by Ipsen at the time of study initiation and conduct. ML: received research grants from Ipsen, NordicNanovector, Novartis, and PentixaPharm. DP and MV: employees of Ipsen. RJH: shares in Telix Pharmaceuticals. No other conflicts of interest exist.